About RepRegen

RepRegen is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in the body. The first platform is focused on bone and other (hard) tissue, whereas the second platform is focused on muscle and other (soft) tissue. A spin-out company from Imperial College London, RepRegen is headquartered within the Imperial College Incubator. RepRegen’s first product is StronBone™ bone graft substitute bioactive glass with Strontium. StronBone and other products in the hard tissue repair and regeneration range are for orthopaedic (trauma and spine) and craniomaxillofacial applications.

RepRegen develops products to repair and restore tissue better and faster. The company’s Smart Biomaterials are designed both to support and to improve cellular growth in vivo. The materials comprise innovations in bioactive ceramics or biomimetic polymer scaffolds. One of the most remarkable RepRegen innovations is the use of Strontium which boosts the formation of bone tissue. Both product lines have significant competitive advantages, on the one hand, by enhancing cellular growth through topography of scaffolds and on the other hand, by the use of specially selected materials.

RepRegen Ltd obtained certification to ISO 13485, 2003 from its notified body on 30 June 2010. This certification is proof that RepRegen's quality management system complies with the applicable parts of the standard.

Notes:

• In the EU, StronBone Bone Graft Substitute is a medical device which has CE Marking approval.
• In the USA, StronBone Bone Graft Substitute is a medical device product which has not yet been cleared through a 510k for clinical use and is available for Research Use Only.